Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis – results from a registry-based study from Germany

Table 1 Tumor characteristics of female patients with primary invasive breast cancer overall and by age

Category		Overall		< 70 years		≥ 70 years
Category		N	% ^a	N	% ^a	N	% ^a
Overall		9359		6138	65.6	3221	34.4
Clinical stage	M1	658	7.0	377	6.1	281	8.7
Death certificate only notification		183	2.0	36	0.6	147	4.6
Study sample		8518	91.0	5725	93.3	2793	86.7
Laterality	available	8508	99.9	5716	99.8	2792	100.0
	unilateral	8306	97.6	5600	98.0	2706	96.9
	synchronous bilateral^b	202	2.4	116	2.0	86	3.1
Clinical stage	available	7447	87.4	5312	92.8	2135	76.4
	T1/2N0	4132	55.5	3011	56.7	1121	52.5
	T1/2N+	2379	31.9	1787	33.6	592	27.7
	T3/4N0	205	2.8	111	2.1	94	4.4
	T3/4N+	731	9.8	403	7.6	328	15.4
Microscopically verified		8482	99.6	5723	100.0	2759	98.8
Morphology	available	8477	99.5	5720	99.9	2757	98.7
	invasive ductal	5883	69.4	4053	70.9	1830	66.4
	invasive lobular	1190	14.0	773	13.5	417	15.1
	mixed type	654	7.7	465	8.1	189	6.9
	other	750	8.8	429	7.5	321	11.6
Histopathologic grade	available	8216	96.5	5564	97.2	2652	95.0
	1	610	7.4	405	7.3	205	7.7
	2	5232	63.7	3458	62.1	1774	66.9
	3/4	2374	28.9	1701	30.6	673	25.4
HR expression	available	7424	87.2	5048	88.2	2376	85.1
	positive^c	6235	84.0	4152	82.3	2083	87.7
	negative	1189	16.0	896	17.7	293	12.3
HER2/neu expression	available	5938	69.7	4051	70.8	1887	67.6
	positive^d	1466	24.7	1054	26.0	412	21.8
	negative	4472	75.3	2997	74.0	1475	78.2
Subtype based on immunohistochemical surrogates	HR and HER2/neu status available	7197	84.5	4883	85.3	2314	82.8
	‚HR positive‘	6235	86.6	4152	85.0	2083	90.0
	‚HER2/neu positive‘^e	368	5.1	278	5.7	90	3.9
	‚triple negative’^f	594	8.3	453	9.3	141	6.1
Follow-up available		8380	98.4	5634	98.4	2746	98.3
		years		years		years
Mean observation time		10.3		10.4		10.3

The overall study sample includes all breast cancer patients (ICD-10 code: C50) from Saarland diagnosed between 1999 and 2009. T, N = T and N category of TNM classification, HR = hormone receptor, HER2/neu = human epidermal growth factor receptor 2. ^afigures printed in normal text represent numbers and proportions of the overall cohort or study sample, figures printed in italic text represent proportions of cases of the respective sample with available information, ^btumors were classified as synchronous bilateral if the time interval between their detection was ≤3 months, ^cincludes tumors with mixed HR expression (either estrogen or progesterone receptor positive), ^dincludes tumors with borderline expression of HER2/neu, ^eHER2/neu positive, but HR negative, ^fboth HR negative and HER2/neu negative

ISSN: 1471-2407